- WPD Pharmaceuticals (WBIO) applies for a temporary management cease trade order
- WPD is seeking the MCTO as it is unable to file its annual filings within the deadline as required under National Instrument 51-102
- WPD anticipates that it will be in a position to file the annual filings on or about May 10, 2021
- WPD is a biotechnology research and development company with a focus on oncology
- WPD Pharmaceuticals Inc. (WBIO) is in the grey and is trading at C$0.29 at 12:47 pm ET
WPD Pharmaceuticals Inc. (WBIO) has applied to the British Columbia Securities Commission for a temporary management cease trade order.
If granted, the order will prohibit trading in securities of WPD Pharmaceuticals by certain insiders of the company, whether direct or indirect.
WPD is seeking the MCTO as it is unable to file its annual filings within the deadline as required under National Instrument 51-102.
WPD anticipates that it will be in a position to file the annual filings on or about May 10, 2021.
It also confirms that it will comply with the alternative information guidelines included in NP 12-203 so long as the Annual Filings are outstanding.
WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.
WPD has licensed in certain countries 10 novel drug candidates with 4 that are in the clinical development stage.
These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD Pharmaceuticals Inc. (WBIO) is in the grey and is trading at C$0.29 at 12:47 pm ET.